CTIS2023-504625-39-00招募中1 期
An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis (VALE) - APL2-C3G-314
Apellis Pharmaceuticals Inc.0 个研究点目标入组 125 人开始时间: 2023年6月23日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 125
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 0 至 65+（—）
- 性别
- All
入选标准
- •Completed participation in Study APL2-C3G-310 through the Week 52 visit requirements., Experienced clinical benefit from pegcetacoplan while participating in the previous trial, in the opinion of the investigator., Must remain on a stable regimen for C3G or IC-MPGN treatment according to the requirements of Study APL2–C3G–310., Received vaccinations against S pneumoniae, N meningitidis (types A, C, W, Y, and B), and H influenzae (type B) according to the requirements of Study APL2-C3G-310 and agree to receive any additional vaccinations recommended according to Advisory Committee on Immunization Practices recommendations for adults or children with complement deficiencies and/or immunocompromising conditions or other similar local applicable guidelines., Female participants of childbearing potential, defined as any woman who has experienced menarche and who is not permanently sterile or postmenopausal, must have a negative urine pregnancy test at visit 1 and must agree to use protocol-defined methods of contraception for the duration of the study through at least 90 days after receiving the last dose of pegcetacoplan., Male participants must agree to use protocol-defined methods of contraception and agree to refrain from donating semen for the duration of the study through at least 90 days after receiving the last dose of pegcetacoplan., Participants above the legal age of consent, in accordance with local regulations, must be willing and able to provide informed consent. The legally authorized representative of participants under the legal age of consent must be willing and able to provide informed consent; where appropriate, participants under the legal age of consent must also give their assent to participation in the study., Willing and able to self-administer pegcetacoplan or have an identified caregiver who can perform the administration.
排除标准
- •Female participants who are or are planning to become pregnant or who are currently breastfeeding and are unwilling to discontinue for the duration of the study and for at least 90 days after the final dose of study drug., Inability or unwillingness to cooperate with the requirements of the protocol., Any condition that, in the opinion of the investigator, creates an undue risk for the participant by participating in the study or is likely to confound interpretation of the study results., Evidence of ongoing drug or alcohol abuse or dependence, in the opinion of the investigator.
研究者
相似试验
进行中（未招募）
1 期
A study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Patients with C3 Glomerulopathy or Immune-Complex Membranoproliferative GlomerulonephritisEUCTR2022-002833-33-CZApellis Pharmaceuticals, Inc.100
进行中（未招募）
1 期
An Open Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long Term Safety and Efficacy of Pegcetacoplan in the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH).EUCTR2019-001106-23-GBApellis Pharmaceuticals, Inc.160
进行中（未招募）
1 期
An Open-label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH)EUCTR2019-001106-23-BGApellis Pharmaceuticals, Inc.160
已完成
3 期
Pegcetacoplan Long-term Safety and Efficacy Extension StudyJPRN-jRCT2031220046chendu Uchendu9
进行中（未招募）
1 期
An Open Label, Non-Randomized, Multi-Center Extension Study to Evaluate the Long Term Safety and Efficacy of APL-2 in the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH).Paroxysmal Nocturnal HemoglobinuriaMedDRA version: 21.1Level: LLTClassification code 10055629Term: Paroxysmal nocturnal hemoglobinuriaSystem Organ Class: 100000004857EUCTR2019-001106-23-ESApellis Pharmaceuticals, Inc.119